Navigation Links
COMBACTE: A new step in the fight against resistance to antibiotics
Date:2/26/2013

ipate in the overall project management.

INSERM and its Midi-Pyrnes/Limousin directorate headed by Armelle Barelli will be responsible for budget management for all the project's clinical trials.

ECRIN (European Clinical Research Infrastructures Network) coordinated by INSERM and headed by Professor Jacques Demotes, is an infrastructure whose purpose is to facilitate the setting up of international trials in Europe. ECRIN will be responsible for the management of the project's clinical trials through its European partners, ensuring coordination between the various national networks.

Dr Laurent Abel (INSERM U980 "Human genetics of infectious diseases"), another French member of the consortium, will participate in the identification in humans of genetic markers affecting the susceptibility/resistance to bacterial infection and the response to their treatment, along with the other partners.

Two French networks will also participate in clinical trials for the COMBACTE project, the Rseau National de Recherche Clinique en Infectiologie (RENARCI) coordinated by Professor Bruno Hoen (Besanon University Hospital), with the support of the Institut Thmatique Multi-Organismes "Microbiologie et Maladies Infectieuses" (IMMI) directed by Professor Jean-Franois Delfraissy, and the CRICS (Clinical Research in Intensive Care and Sepsis) network, headed by Dr Bruno Franois and Professor Pierre-Franois Dequin at the Tours University Hospital. The Groupe pour la Recherche et l'Enseignement en Pneumo-Infectiologie (a Working Party emanating from the Socit de Pneumologie de Langue Franaise) coordinated by Professor Anne Bergeron at the AP-HP Saint-Louis with the collaboration of Dr Muriel Fartoukh at the APHP Tenon will be associated with the CRICS network.

COMBACTE, a unique excellence project with international visibility

COMBACTE is the European public/private partnership set up for the development of drugs.

The development of new
'/>"/>

Contact: Elodie PFENDER
elodie.pfender@chu-limoges.fr
33-055-505-8837
INSERM (Institut national de la sant et de la recherche mdicale)
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Scientists find bone-marrow environment that helps produce infection-fighting T and B cells
2. Compound stimulates tumor-fighting protein in cancer therapy
3. In a fight to the finish, Saint Louis University research aims knockout punch at hepatitis B
4. Planning for bacteria in cancer patients may help hospitals fight infections
5. La Jolla Institute identifies molecular switch enabling immune cells to better fight disease
6. New insights into how immune system fights atherosclerosis
7. University of Tennessee researchers find fungus has cancer-fighting power
8. Compound in grapes, red wine could be key to fighting prostate cancer
9. Immune system fighters speak in patterns of proteins, prefer squishy partners
10. Fighting melanomas attraction to the brain
11. An important breakthrough in the fight against muscular dystrophies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Calif. (Sept. 17, 2014) A rare genetic disorder known ... to a recent joint investigation by researchers at San ... Diego. In addition to suggesting better treatment options for ... clues into the genetic underpinnings of autism., Jacobsen syndrome ... National Institutes of Health. It occurs in a person ...
(Date:9/17/2014)... and their environmental impact recently scored a major win. ... on the bags, and Governor Jerry Brown is expected ... not yielding without a fight, according to an article ... newsmagazine of the American Chemical Society. , Alexander Tullo, ... campaign logged its first small victory in 1990 when ...
(Date:9/17/2014)... in Biomedical Informatics at IMIM (Hospital del Mar Medical ... (UPC) have recently published a study in eLife ... important role in the evolution of new proteins, some ... be discovered., Ribosomes produce proteins from the instructions found ... human genome is RNA containing information for the synthesis ...
Breaking Biology News(10 mins):A link between Jacobsen syndrome and autism 2Parts of genome without a known function may play a key role in the birth of new proteins 2
... African sanctuaries carry drug-resistant, human-associated strains of the bacteria ... chimpanzees could spread to endangered wild ape populations if ... study shows. The study by veterinarians, microbiologists and ... sequencing technology of bacterial genomes used in hospitals to ...
... forget-me-nots have been added to Flora of New Zealand . ... Island during an expedition led by Dr. Carlos A. Lehnebach. These ... the open access journal PhytoKeys . The expedition ... at the Museum of New Zealand Te Papa Tongarew a ...
... faces far greater change and risk of large-scale extinctions than ... the world,s leading marine scientists has warned. The researchers ... UK have compared events which drove massive extinctions of sea ... taking place in the seas and oceans globally today. ...
Cached Biology News:Sanctuary chimps show high rates of drug-resistant staph 2No ordinary forget-me-nots 2Sea life 'facing major shock' 2Sea life 'facing major shock' 3
(Date:9/18/2014)... Sept. 18, 2014   Sigma-Aldrich Corporation ... has entered into a new gene editing partnership ... Vector Core. Under the partnership, Sigma-Aldrich will provide ... design consultation, and dedicated gene editing bioinformaticians. ... editing-based research at the U-M Medical School. One ...
(Date:9/18/2014)... 2014 SeqLL Inc., the owner ... announced today the closing of a $1M Series-A ... Genomic Diagnostic Technologies, will increase the power of ... Founded in March 2013 by Daniel Jones, a ... Helicos BioSciences, SeqLL has continued to offer Helicos’ ...
(Date:9/18/2014)... lab can be pretty expensive. Now a team led ... an open-source library of designs that will let scientists ... equipment: the syringe pump. , Syringe pumps are used ... delivery or mixing chemicals in a reaction. They can ... Joshua Pearce and his team of Michigan Tech students ...
(Date:9/18/2014)... a new microscopy technology that allows them to ... resolution. , Dubbed "Complementation Activated Light Microscopy" (CALM), ... an order of magnitude finer than conventional optical ... biomolecules at the nanometer scale. , In a ... Communications , the researchers behind CALM used it ...
Breaking Biology Technology:Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2Doing science just got cheaper -- and faster 2Scientists pioneer microscopy technique that yields fresh data on muscular dystrophy 2
... to Screen Donated Blood for Hepatitis B, as well ... and Semi-Automated Instrument Systems -, SAN DIEGO, Aug. ... that the US Food and Drug Administration,(FDA) has approved ... to screen donated blood for the hepatitis B,virus (HBV). ...
... Stock Exchange Symbol: MS, - Milestone triggers ... - EDMONTON, Aug. 13 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), today,announced that the ... trial has conducted the scheduled interim analysis of ...
... Mentice, Inc. and MATC have,forged a relationship that ... multiple,and mutually beneficial projects to further advance the ... throughout North America., Mentice,s Procedicus VIST Simulator ... physician to gain exposure to routine,and sophisticated procedures. ...
Cached Biology Technology:FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 2FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 3FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 4BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 2BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 3BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 4Mentice, Inc. and the Milwaukee Area Technical College (MATC) Announce Their Partnership in the Area of Procedural Medical Simulation 2
... an inhibitor of caspase-3/7 ... of inhibitor required to ... be determined empirically for ... inhibitor is sufficient to ...
...
SNARE associated protein snapin, clone MGC:2717...
Human OSCAR MAb (Clone 259501)...
Biology Products: